Expert view: ddPCR whole cell DNA workflow efficiently measures success of CAR T-cell production

Posted: 10 September 2020 | | No comments yet

Not every step of CAR T-cell manufacturing can be tightly regulated, introducing some significant quality control challenges for companies developing CAR T cancer therapies

For example, when scientists transduce a population of T cells with the CAR gene using the virus, the transduction of the gene into the genome needs to be at a level that it does not have too many or too few events. Knowing the percent transduction efficiency of the cells helps ensure that the treatment is safe and effective.

    To read this expert view in full, please complete the form below:


    This specialist content is provided to you free-of-charge thanks to the kind support of Bio-Rad

    By clicking submit you confirm that you accept our terms and conditions and privacy policy.

    Related organisations

    Leave a Reply

    Your email address will not be published. Required fields are marked *